Materials and Methods: In this study, the NMRI adult male mice were anesthetized. To induce the Parkinson's animal model, a 22 gauge cannula was placed into the left Substantia Nigra pars compacta and then 6-hydroxydopamine was infused to Substantia Nigra pars compacta More
Materials and Methods: In this study, the NMRI adult male mice were anesthetized. To induce the Parkinson's animal model, a 22 gauge cannula was placed into the left Substantia Nigra pars compacta and then 6-hydroxydopamine was infused to Substantia Nigra pars compacta through a 30-gauge cannula. The group control1 received saline on the left side of the Substantia Nigra pars compacta.Then, to investigate the effect of the Naringenin, group control2 received distilled water and other groups received Naringenin via gavage for two weeks, and apomorphine induced rotation, catalepsy, and behavioral tests were assessed in all groups. Hematoxylin and eosin staining was performed and the percentage of the neurons on the left side of the Substantia Nigra pars compacta were calculated. In this study, in cell culture model, dopaminergic-like neurons cultured in DMEM medium were counted, and cells were used and incubated to evaluate the effect of naringinin against 6-hydroxy dopamine. Concentrations were 50 for 6-hydroxy dopamine solution and 0.25, 0.1 and 0.01 for NAR solution. Finally, cell viability was assessed using MTT and trypan blue methods.Results: 6-Hydroxy dopamine increased catalepsy and contralateral turns compared to the control group. Naringin reduced catalapsy and contralateral turns, it reduced anxiety and depressive-like behaviours besides that it increased swimming time and locomotor activity compared to the control group. Conclusion: it seems that Naringin is a therapeutic option for neurodegenerative disorders, such as Parkinson's disease.
Manuscript profile
Since limited studies have evaluated the antioxidant effects of magnesium oxide nanoparticles on Parkinson's disease, the aim of this study is to investigate the effect of magnesium oxide nanoparticles (MON) on oxidative stress in the Parkinson's model in mice. In this More
Since limited studies have evaluated the antioxidant effects of magnesium oxide nanoparticles on Parkinson's disease, the aim of this study is to investigate the effect of magnesium oxide nanoparticles (MON) on oxidative stress in the Parkinson's model in mice. In this experimental study, 54 adult male rats were divided into nine groups of six, including: healthy control group, parkinsonian control group receiving 6-hydroxydopamine in the lateral ventricle, sham group receiving normal saline and healthy experimental group receiving magnesium oxide nanoparticles in doses of 2.5, 5 and 10 mg/kg and experimental Parkinson's groups that in addition to inducing Parkinson's, received magnesium oxide nanoparticles in doses of 2.5, 5 and 10 mg/kg. Administration of nanoparticles was intraperitoneal for 30 days. After that, oxidative stress parameters MDA, CAT and SOD were measured in the brain tissue. The results of the present study showed that treatment with magnesium oxide nanoparticles significantly reduced the amount of oxidative stress parameters in the brain tissue (p < 0.05). Magnesium oxide nanoparticle treatment in doses of 5 and 10 mg/kg decreased MDA in parkinsonian groups compared to parkinsonian control animals. Also, the treatment of magnesium oxide nanoparticles in doses of 5 and 10 mg/kg in the parkinsonian group caused a significant increase in the activity of SOD and CAT enzymes compared to parkinsonian control animals. As a result, it can be said that magnesium oxide nanoparticle can play a promising role with its effectiveness in reducing oxidative stress processes in Parkinson's model.
Manuscript profile
Parkinson's disease is one of the most common types of the neurodegenerative disease, which is characterized by the movement disorders such as slowness, lack of movement, muscle stiffness, and resting tremor, and hypophonic. The main reason of disease is the destruction More
Parkinson's disease is one of the most common types of the neurodegenerative disease, which is characterized by the movement disorders such as slowness, lack of movement, muscle stiffness, and resting tremor, and hypophonic. The main reason of disease is the destruction of dopaminergic neurons in the Substantia Nigra in the midbrain and a decrease in dopamine concentration in the striatum terminals. In this study, used culture medium was DMEM with FBS, and the cells under study were catecholaminergic cells.6-Hydroxy dopamine toxin was used on cells to create a Parkinson cell model. Curcumin was used as a drug, and MTT, and BT methods were used to count the living cells. This research was designed to study the curcumin effect on Parkinson's disease with cellular model induced by 6-Hydroxy dopamine toxin with reduced inflammation. This study's results showed that using curcumin can increase the antioxidant power and protect the cell from damage caused by reactive oxygen species. Due to the results of MTT, and curcumin treatment due to its anti-inflammatory properties BT test also showed that cellular protection had increased, the death of aminergic catechol cells by 6-hydroxy dopamine toxin was significantly reduced. It shows the antioxidant and anti-inflammatory effects of curcumin on the damage caused by Parkinson's disease and reducing the progression of symptoms. Treatment withcurcumin to be anti-inflammatory can reduce the death of catecholaminergic cells by 6-hydroxy dopamine toxin.
Manuscript profile
Sanad
Sanad is a platform for managing Azad University publications
